Insider Transactions in Q2 2022 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2022
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
11,689
-9.52%
|
$3,401,499
$291.3 P/Share
|
|
May 31
2022
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
311
-0.62%
|
$84,281
$271.24 P/Share
|
|
May 18
2022
|
Suketu Upadhyay Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,558
+50.0%
|
-
|
|
May 17
2022
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Bona fide gift
|
Indirect |
1,672
-13.14%
|
-
|
|
May 16
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
133
-0.18%
|
$33,516
$252.61 P/Share
|
|
May 16
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
133
-0.03%
|
$33,250
$250.37 P/Share
|
|
May 16
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
45
-0.02%
|
$11,340
$252.56 P/Share
|
|
May 04
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
36
-0.09%
|
$9,900
$275.09 P/Share
|
|
May 02
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
343
-0.11%
|
$88,837
$259.61 P/Share
|
|
May 02
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
737
-1.66%
|
$190,883
$259.81 P/Share
|
|
May 02
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
320
-0.11%
|
$82,880
$259.66 P/Share
|
|
May 02
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
306
-0.47%
|
$80,478
$263.98 P/Share
|
|
May 01
2022
|
Lloyd Carney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,449
+17.46%
|
-
|
|
May 01
2022
|
Margaret G Mcglynn Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
921
-83.8%
|
-
|
|
May 01
2022
|
Sangeeta N. Bhatia Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,449
+17.91%
|
-
|
|
May 01
2022
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,449
+33.44%
|
-
|
|
May 01
2022
|
Diana Mckenzie Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,842
-56.21%
|
-
|
|
May 01
2022
|
Terrence C Kearney Director |
BUY
Grant, award, or other acquisition
|
Direct |
725
+9.98%
|
-
|
|
Apr 29
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
766
-1.79%
|
$211,416
$276.17 P/Share
|
|
Apr 29
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
547
-1.25%
|
$150,972
$276.17 P/Share
|
|
Apr 29
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
120
-0.17%
|
$33,000
$275.7 P/Share
|
|
Apr 25
2022
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
327
-2.21%
|
$87,963
$269.25 P/Share
|
|
Apr 18
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-16.11%
|
$568,000
$284.68 P/Share
|
|
Apr 18
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 14
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-16.4%
|
$578,000
$289.45 P/Share
|
|
Apr 14
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 13
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
15,789
-17.55%
|
$4,563,021
$289.04 P/Share
|
|
Apr 13
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-8.57%
|
$572,000
$286.7 P/Share
|
|
Apr 13
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 12
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-15.97%
|
$562,000
$281.17 P/Share
|
|
Apr 12
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 11
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-20.71%
|
$560,000
$280.67 P/Share
|
|
Apr 11
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 08
2022
|
Margaret G Mcglynn Director |
SELL
Open market or private sale
|
Direct |
5,000
-44.34%
|
$1,400,000
$280.84 P/Share
|
|
Apr 08
2022
|
Margaret G Mcglynn Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.05%
|
$635,000
$127.54 P/Share
|
|
Apr 08
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
1,907
-26.87%
|
$533,960
$280.2 P/Share
|
|
Apr 08
2022
|
Sangeeta N. Bhatia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,907
+21.18%
|
$238,375
$125.71 P/Share
|
|
Apr 08
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-16.44%
|
$556,000
$278.41 P/Share
|
|
Apr 08
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 07
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
561
-0.43%
|
$154,836
$276.37 P/Share
|
|
Apr 07
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-13.17%
|
$550,000
$275.04 P/Share
|
|
Apr 07
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 06
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-14.36%
|
$540,000
$270.72 P/Share
|
|
Apr 06
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 05
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-11.09%
|
$542,000
$271.84 P/Share
|
|
Apr 05
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 05
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
3,163
-6.8%
|
$869,825
$275.23 P/Share
|
|
Apr 04
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-20.42%
|
$534,000
$267.14 P/Share
|
|
Apr 04
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 04
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
562
-0.6%
|
$150,054
$267.76 P/Share
|